Search results
Showing 8026 to 8040 of 8973 results
This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)
This guidance has been updated and replaced by NICE HealthTech guidance 770.
Discontinued Reference number: GID-TA10843
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
In development Reference number: GID-TA11655 Expected publication date: TBC
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
Discontinued Reference number: GID-MT130
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
In development Reference number: GID-TA11481 Expected publication date: TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Discontinued Reference number: GID-TA11442
Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]
Discontinued Reference number: GID-TA10401
Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]
Discontinued Reference number: GID-TA10443
Discontinued Reference number: GID-TA10445
Discontinued Reference number: GID-SGWAVE0701
Discontinued Reference number: GID-SGWAVE0761